I.V. Selonabant in Healthy Adult Subjects
← catalyst calendarSponsored by Anebulo Pharmaceuticals (industry) · ANEB — their whole pipeline →. With National Institute on Drug Abuse (NIDA).
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
40actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-22 | actual | When the study began enrolling |
| Primary completion | 2026-05-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-06 | actual | The whole study's end, after follow-up |
| First posted | 2025-10-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: selonabant — also filed as ANEB-001
- Drug: placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Adverse Events
measured 28 days
Number of Participants with Clinically Significant Laboratory Test Results
measured 28 days
Number of Participants with Clinically Significant Vital Signs Values
measured 28 days
Number of Participants with Clinically Significant Abnormal ECG Findings
measured 28 days
Number of Participants with Clinically Significant Abnormal Physical Exam Findings
measured 28 days
Change from Baseline in Beck Depression Inventory (BDI)
measured 28 days
Change from Baseline in Columbia Suicide Severity Rating Scale (C-SSRS)
measured 28 days
Area Under the Concentration-time Curve From Zero Time to Time of Last Quantifiable Concentration
measured 28 days
Terminal Elimination Phase Half-life (T1/2)
measured 28 days
Maximum Observed Concentration (Cmax)
measured 28 days
Pharmacokinetic Clearance (CL)
measured 28 days
Permalink · ANEB's whole pipeline · Catalyst calendar · Every registered study · What changed